Novel drug, NFX-179, inhibits MEK activity, prevents cutaneous squamous cell carcinoma development
Pre-clinical studies find topical application of NFX-179 gel efficacious with no toxicities
2023-10-11
(Press-News.org) TAMPA, Fla. — Cutaneous squamous cell carcinoma is the second most common type of skin cancer in the United States, impacting approximately 700,000 people each year. While medications exist to prevent the development of disease, they are associated with side effects, suggesting the need for new drugs that can be safely used to prevent it. In a new article published today in Science Translational Medicine, a team of Moffitt Cancer Center researchers, in collaboration with NFlection Therapeutics and researchers at Stanford University, reports the identification of a new drug, NFX-179, that can be applied to the skin and was shown to prevent the development of cutaneous squamous cell carcinoma in pre-clinical models.
Cutaneous squamous cell carcinoma is an extremely common malignancy and while most cases can be treated by surgical removal, approximately 5% of cases are more advanced and require additional therapy. Given the high incidence of cutaneous squamous cell carcinoma and mortality associated with advanced disease, researchers have been trying to develop drugs that can be used to prevent disease development.
“Our previous work showed that the canonical mitogen-activated protein kinase (MAPK) signaling pathway is important for the development of cutaneous squamous cell carcinoma. Our new study expanded on this, by showing that drugs that target the extracellular signal-regulated kinase (ERK) MAPK pathway, including MAP2K / MEK inhibitors, may be an effective approach to prevent the development of cutaneous squamous cell carcinoma,” said Kenneth Tsai, M.D., Ph.D., vice chair of Research Pathology and senior member of the Cancer Biology & Evolution Program.
While several MEK inhibitors are already approved to treat advanced cancers, such as melanoma and non-small cell lung cancer, these drugs must be given orally and are associated with side effects that would limit their continuous use, particularly in the context of cancer prevention.
Tsai and a team of researchers sought to develop a drug to specifically target the MEK1/2 proteins that could be applied topically on a regular basis. Because of its continuous use, they also needed the drug to have minimal to no side effects. Therefore, the drug had to penetrate the upper epidermal and lower dermal layers of the skin while retaining high potency and being rapidly cleared from circulation to limit side effects.
The researchers designed and screened over 100 compounds and identified the drug NFX-179 that fit their requirements. They performed a series of pre-clinical experiments in mouse models and discovered that a gel formulation of NFX-179 reduced the formation of new cutaneous squamous cell carcinomas by up to 92% at the highest doses. Additionally, the effects of the NFX-179 gel were localized, as inhibition of cutaneous squamous cell carcinoma development was observed only in areas that were treated with the drug, and no systemic toxicities were observed.
“Our data provide compelling rationale for using metabolically labile topical MEK inhibitors such as NFX-179 as an effective strategy for cutaneous squamous cell carcinoma chemoprevention. NFX-179 gel appears safe, tolerable and highly efficacious in pre-clinical model systems,” Tsai said.
This study was supported by NFlection Therapeutics, the National Institutes of Health (P30-CA076292, 5K23CA211793, 75N91019C00019), the Damon Runyon Cancer Research Foundation (CI-104-19) and Moffitt’s Donald A. Adam Melanoma & Skin Cancer Center of Excellence.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 56 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 8,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
###
END
ELSE PRESS RELEASES FROM THIS DATE:
2023-10-11
HOUSTON ― The University of Texas MD Anderson Cancer Center will host its annual Leading Edge of Cancer Research Symposium Nov. 16-17, 2023, featuring presentations and discussions on genomics, immunity and inflammation, computational approaches for spatial biology, and emerging technologies that are driving the next wave of cancer breakthroughs.
The in-person symposium at MD Anderson will include keynote presentations from Paul Mischel, M.D., professor of Pathology at Stanford University, Andrea Schietinger, Ph.D., associate professor of Immunology at Memorial Sloan Kettering Cancer Center, and Kevan Shokat, Ph.D., chair of Cellular and Molecular Pharmacology at University ...
2023-10-11
Speech production is a complex neural phenomenon that has left researchers explaining it tongue-tied. Separating out the complex web of neural regions controlling precise muscle movement in the mouth, jaw and tongue with the regions processing the auditory feedback of hearing your own voice is a complex problem, and one that has to be overcome for the next generation of speech-producing protheses.
Now, a team of researchers from New York University have made key discoveries that help untangle that web, and are using it to build vocal reconstruction technology that recreates the voices of patients ...
2023-10-11
CORVALLIS, Ore. – Researchers in the Oregon State University College of Engineering are spearheading a $2 million federal effort to explore new ways of developing electrical components that are better able to withstand extreme operating conditions, especially high temperatures.
The team will try to find novel, artificial-intelligence-based methods for designing and building long-lasting, high-efficiency electrical components for harsh-environment applications such as high-power radar and the aerospace, automotive and wireless communications industries.
“The semiconductor ...
2023-10-11
The National Science Foundation is funding a $13.9 million program led by the University of Alaska Fairbanks to help multiple communities respond to coastal erosion, flooding, permafrost thaw and other hazards attributed to climate change.
The four years of funding is part of the foundation’s Navigating the New Arctic program.
The funding supports AC³TION, a project led by the Alaska Coastal Cooperative at UAF in collaboration with the rural coastal communities, Arizona State University, the University of Northern Iowa and the University of Texas El Paso.
The group’s acronym stands for Alaska Coastal Cooperative for Co-producing Transformative Ideas and Opportunities ...
2023-10-11
MINNEAPOLIS – Among people who report memory and thinking problems, some show no signs of a problem on standard tests, while others have subtle declines on their tests. A new study shows that people who have subtle problems with these tests may have an increased risk of developing mild cognitive impairment, which can be a precursor to dementia. The study is published in the October 11, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
“Several studies have found that people with subjective ...
2023-10-11
MINNEAPOLIS – New guidance has been issued for clinicians on the determination of brain death, also known as death by neurologic criteria. A new consensus practice guideline, developed through a collaboration between the American Academy of Neurology (AAN), the American Academy of Pediatrics (AAP), the Child Neurology Society (CNS), and the Society of Critical Care Medicine (SCCM) is published in the October 11, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
This guideline updates the 2010 AAN ...
2023-10-11
“The present study is among few to examine racial/ethnic disparities in dementia risk and their related pathways [...]. It is the first to do so in a UK population.”
BUFFALO, NY- October 11, 2023 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 18, entitled, “Pathways explaining racial/ethnic and socio-economic disparities in dementia incidence: the UK Biobank study.”
Pathways explaining racial/ethnic disparities ...
2023-10-11
“[...] our approach enables mechanistic studies of drug resistance with 3D cultures of primary cancer cells to develop and test treatments that suppress cancer [...].”
BUFFALO, NY- October 11, 2023 – A new research paper was published in Oncotarget's Volume 14 on October 4, 2023, entitled, “Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells.”
Drug resistance is a major barrier against successful treatments of cancer patients. Gain of stemness under drug pressure is a major mechanism that renders treatments ineffective. Identifying ...
2023-10-11
Orchids, mosses, ferns—or epiphytes, defined as nonparasitic plants that grow on other plants—are crucial for Earth’s biodiversity and play essential roles in forests around the world, building habitat in trees for myriad other life forms, from bacteria and insects to birds and reptiles.
However, the very attributes that have enabled epiphytes to thrive in forest canopies are now making them vulnerable to both natural and human-caused disturbances, according to Nalini Nadkarni, the University of Utah biologist renowned for her pioneering work studying and conserving treetop ecosystems.
In a study published this month, Nadkarni found these vital plants ...
2023-10-11
What type of brain tumor does this patient have? AI technology helps to determine this as early as during surgery, within 1.5 hours. This process normally takes a week. The new technology allows neurosurgeons to adjust their surgical strategies on the spot. Today, researchers from UMC Utrecht and researchers, pathologists and neurosurgeons from the Princess Máxima Center for pediatric oncology and Amsterdam UMC have published about this study in Nature.
Every year, 1,400 adults and 150 children are diagnosed with a tumor in the brain or spinal cord in the Netherlands. Surgery is often the ...
LAST 30 PRESS RELEASES:
[Press-News.org] Novel drug, NFX-179, inhibits MEK activity, prevents cutaneous squamous cell carcinoma development
Pre-clinical studies find topical application of NFX-179 gel efficacious with no toxicities
